Literature DB >> 11676961

Effect of successful electrical cardioversion on serum aldosterone in patients with persistent atrial fibrillation.

A Goette1, P Hoffmanns, W Enayati, U Meltendorf, J C Geller, H U Klein.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2001        PMID： 11676961     DOI： 10.1016/s0002-9149(01)01905-1

Source DB:  PubMed          Journal:  Am J Cardiol        ISSN： 0002-9149            Impact factor:   2.778


× No keyword cloud information.
  26 in total

Review 1.  Impact of aldosterone antagonists on the substrate for atrial fibrillation: aldosterone promotes oxidative stress and atrial structural/electrical remodeling.

Authors:  Fadia Mayyas; Karem H Alzoubi; David R Van Wagoner
Journal:  Int J Cardiol       Date:  2013-08-15       Impact factor: 4.164

Review 2.  Arterial Hypertension, Atrial Fibrillation, and Hyperaldosteronism: The Triple Trouble.

Authors:  Teresa M Seccia; Brasilina Caroccia; Gail K Adler; Giuseppe Maiolino; Maurizio Cesari; Gian Paolo Rossi
Journal:  Hypertension       Date:  2017-04       Impact factor: 10.190

3.  Chronic atrial ionic remodeling by aldosterone: potentiation of L-type Ca2+ channels and its arrhythmogenic significance.

Authors:  Erick B Ríos-Pérez; Maricela García-Castañeda; Adrián Monsalvo-Villegas; Guillermo Avila
Journal:  Pflugers Arch       Date:  2016-09-15       Impact factor: 3.657

4.  Aldosterone-receptor antagonism as a potential therapeutic option for atrial fibrillation.

Authors:  Uwe Lendeckel; Dobromir Dobrev; Andreas Goette
Journal:  Br J Pharmacol       Date:  2010-04       Impact factor: 8.739

Review 5.  EHRA/HRS/APHRS/SOLAECE expert consensus on atrial cardiomyopathies: Definition, characterization, and clinical implication.

Authors:  Andreas Goette; Jonathan M Kalman; Luis Aguinaga; Joseph Akar; Jose Angel Cabrera; Shih Ann Chen; Sumeet S Chugh; Domenico Corradi; Andre D'Avila; Dobromir Dobrev; Guilherme Fenelon; Mario Gonzalez; Stephane N Hatem; Robert Helm; Gerhard Hindricks; Siew Yen Ho; Brian Hoit; Jose Jalife; Young-Hoon Kim; Gregory Y H Lip; Chang-Sheng Ma; Gregory M Marcus; Katherine Murray; Akihiko Nogami; Prashanthan Sanders; William Uribe; David R Van Wagoner; Stanley Nattel
Journal:  Heart Rhythm       Date:  2016-06-10       Impact factor: 6.343

Review 6.  Management of primary aldosteronism and mineralocorticoid receptor-associated hypertension.

Authors:  Satoshi Morimoto; Atsuhiro Ichihara
Journal:  Hypertens Res       Date:  2020-05-18       Impact factor: 3.872

Review 7.  Arterial Hypertension, Aldosterone, and Atrial Fibrillation.

Authors:  Teresa M Seccia; Brasilina Caroccia; Giuseppe Maiolino; Maurizio Cesari; Gian Paolo Rossi
Journal:  Curr Hypertens Rep       Date:  2019-11-18       Impact factor: 5.369

8.  Prolongation of PR interval is associated with endothelial dysfunction and activation of vascular repair in high-risk cardiovascular patients.

Authors:  Yap-Hang Chan; Chung-Wah Siu; Kai-Hang Yiu; Yuen-Fung Yiu; Kui-Kai Lau; Tai-Hing Lam; Chu-Pak Lau; Hung-Fat Tse
Journal:  J Interv Card Electrophysiol       Date:  2013-02-07       Impact factor: 1.900

9.  Effects of spironolactone on atrial structural remodelling in a canine model of atrial fibrillation produced by prolonged atrial pacing.

Authors:  J Zhao; J Li; W Li; Y Li; H Shan; Y Gong; B Yang
Journal:  Br J Pharmacol       Date:  2010-01-15       Impact factor: 8.739

10.  Absence of protective effect of renin-angiotensin system inhibitors on atrial fibrillation development: insights from the Canadian Trial of Atrial Fibrillation (CTAF).

Authors:  Maryse Palardy; Anique Ducharme; Stanley Nattel; Jean-Claude Tardif; Michel White; Normand Racine; Karine Tétreault; Farida Dabouz; Mario Talajic; Denis Roy
Journal:  Can J Cardiol       Date:  2008-09       Impact factor: 5.223
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.